Guest Columns & From The Editor

  1. Part 2: ISCT’s Miguel Forte On The Society’s Near-Term Goals
    10/16/2018

    In part two of my discussion with Miguel Forte, CEO at Zelluna Immunotherapy and ISCT’s Chief Commercialization Officer, he answers my questions about the Society’s near-term goals and objectives as well as his top areas of focus as CCO.

  2. CMC For Cell & Gene Therapies — 4 Topics To Discuss During Pre-IND Meetings With FDA
    10/11/2018

    Seeking early guidance from regulators can be invaluable when navigating preliminary product development strategies. The need for feedback increases significantly when working with cell and gene therapy products (CT/GT). These therapies, once considered a kind of “wild-west,” are becoming more widely accepted. Still, the task of seeking approval from the FDA can be extremely challenging. It’s become vital to get your relationship with the FDA off to a solid start from day one.

  3. State Of The Cell And Gene Therapy Sector — Clinical, Financial, And Regulatory Perspectives
    10/4/2018

    The regenerative medicine sector is at a remarkable moment. Transformative products are now on the market and accessible to greater numbers of patients every day. Dozens of additional therapies are in late stage studies. The regulatory and policy environment has evolved rapidly alongside the science, enabling a surge of incoming innovation.

  4. Science Driving Gene Therapy Development At bluebird bio
    10/3/2018

    For patients with sickle cell anemia, just getting through the day can be a struggle. Symptoms of the disease include vision problems, swelling of the hands and feet, and periodic episodes of pain that can last from a few hours to a few weeks. In this article Nick Leschly, CEO at bluebird bio, discusses the progress being made with its investigational gene therapy for sickle cell disease.

  5. ISCT’s Miguel Forte On Academic-To-Industry Translation
    10/2/2018

    In part one of my discussion with Miguel Forte, CEO at Zelluna Immunotherapy and Chair of Commercialization Committee at ISCT, he answers my questions about academic-to-industry translation, the root cause of unproven therapies, how the industry is combatting them, and more.

  6. 4 Barriers To Cell And Gene Therapy Development For Rare Diseases — And How To Overcome Them
    9/27/2018

    A number of challenges are hindering efforts to develop cell and gene therapies to treat rare diseases, including pricing and reimbursement, the high cost of bringing these drugs to market, unique manufacturing and supply chain challenges, and our current limited understanding of disease pathology and progression. While these challenges may seem common across other drug markets, in the case of rare diseases, these challenges are exacerbated by limited patient populations

  7. Bridging The Public Knowledge Gap Around Cell And Gene Medicine
    9/20/2018

    According to a review of recent research studies that measured U.S. public opinion related to gene medicine, the public is not yet aware of gene medicine, is unfamiliar with the terms being used to describe the topic, and, when faced with multiple therapeutic options, is worried about making informed decisions.

  8. CAR-T And The Voice Of The Patient
    9/18/2018

    Cell & Gene Editorial Advisory Board member answers questions about his message to pharma executives, researchers, scientists, and doctors, what the industry should consider when developing new payment structures, and more.

  9. Clinical Trial Networks: Overcoming The Complexities Of Regenerative Medicine Studies
    9/13/2018

    The FDA’s RMAT and breakthrough designations have created a streamlined environment for product sponsors. To effectively leverage this regulatory policy environment, sponsors must conduct high-quality clinical trials that are often operationally complex. Clinical trial networks, capable of managing the array of regenerative medicine technologies, are well suited to manage this complexity.

  10. The FDA’s Dr. Peter Marks On The Current State Of Cell And Gene Therapies
    9/11/2018

    Peter Marks, MD, PhD, Director Center for Biologics Evaluation and Research at U.S. Food and Drug Administration answered some of my questions about the current state of the FDA’s regulations around cell and gene therapies, its stance on international harmonization required to make cell and gene therapies more streamlined, the reasons why it is critical for companies to begin working with the FDA early in the development process, and more. Read on for Dr. Marks' insightful responses.